NASDAQ:KURA - Kura Oncology Stock Price, Forecast & News

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Kura Oncology Inc (NASDAQ:KURA) released its earnings results on Tuesday, November, 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.03. View Kura Oncology's Earnings History.

Kura Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Kura Oncology.

8 brokerages have issued twelve-month price objectives for Kura Oncology's shares. Their forecasts range from $22.00 to $30.00. On average, they anticipate Kura Oncology's share price to reach $26.83 in the next twelve months. This suggests a possible upside of 127.4% from the stock's current price. View Analyst Price Targets for Kura Oncology.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.

News articles about KURA stock have been trending very negative recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Kura Oncology earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Kura Oncology.

Kura Oncology saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 2,000,000 shares, a decline of 10.7% from the December 15th total of 2,240,000 shares. Based on an average daily trading volume, of 283,700 shares, the days-to-cover ratio is presently 7.0 days. Currently, 4.9% of the shares of the company are sold short. View Kura Oncology's Current Options Chain.

Some companies that are related to Kura Oncology include Turning Point Therapeutics (TPTX), Aurinia Pharmaceuticals (AUPH), Heron Therapeutics (HRTX), Prestige Consumer Healthcare (PBH), Eidos Therapeutics (EIDX), Aimmune Therapeutics (AIMT), Xencor (XNCR), Cambrex (CBM), Ironwood Pharmaceuticals (IRWD), Principia Biopharma (PRNB), Forty Seven (FTSV), Pacira Biosciences (PCRX), Insmed (INSM), Akcea Therapeutics (AKCA) and Zymeworks (ZYME).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX) and Amicus Therapeutics (FOLD).

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KURA stock can currently be purchased for approximately $11.80.

Kura Oncology has a market capitalization of $534.66 million. The company earns $-60,450,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.View Additional Information About Kura Oncology.

The official website for Kura Oncology is http://www.kuraoncology.com/.

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]